Clinical trial
AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects
NCT00443326 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00443326 |
|---|---|
| Title | AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis Subjects |
| Official title | A Randomized, Double-blind, Placebo-controlled, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of AMG 714 After Multiple Dose Administration in Subjects With Moderate to Severe Psoriasis |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | AMG 714 |
| Enrollment | 22 |
| Start date | Mar 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2010 |
| First posted | Mar 5, 2007 |
| Last update posted | Jan 20, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: